Food Effect Study of IDX-1197 in Healthy Subjects

A Randomized, Open-label, Single-dose, Crossover Phase 1 Clinical Trial to Evaluate the Effects of Food or Ethnicity on the Pharmacokinetics and Safety/Tolerability of IDX-1197 After Single Oral Administration in Healthy Male Korean, Chinese, and Caucasian Volunteers

Study to Evaluate the Effects of Food or Ethnicity on the Pharmacokinetics and Safety/Tolerability of IDX-1197 After Single Oral Administration in Healthy Male Korean, Chinese, and Caucasian Volunteers

Study Overview

• Status: Completed
• Conditions: Healthy Male
• Intervention / Treatment: Drug: IDX-1197(After a meal); Drug: IDX-1197(fasting)

• Study Type: Interventional
• Enrollment (Actual): 37
• Phase: Phase 1

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of
    • Seoul National University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Healthy male Korean, Chinese, or Caucasian adults at the age of ≥19 to ≤50 years old at the time of written informed consent:
2. Body weight ≥55.0 kg AND body mass index (BMS) ≥18.0 kg/m2 to <30.0 kg/m2 at screening: BMI(kg/m2) = body weight (kg) / {height (m)}2
3. The subject must voluntarily decide to participate in the study after being informed of, and fully understanding, details of the study; written informed consent must be obtained prior to any of the screening procedures.
4. Eligible for this study as determined by the investigator based on physical examinations, clinical laboratory tests, and interviews.

Exclusion Criteria:

1. Evidence or history of clinically significant hepatic, renal, neurological, respiratory, endocrine, blood and tumor, cardiovascular, urinary, and psychiatric disorders.
2. Evidence or history of gastrointestinal disorders (gastrointestinal ulcer, gastritis, gastrodynia, gastroesophageal reflux disease, Crohn's disease, etc.) that might affect the safety and PK of IP and/or history of gastrointestinal surgery (except for simple appendectomy and hernia repair).
3. Hypersensitivity to drugs or history of any clinically significant hypersensitivity.

4. Any of the following screening test results:

   • Hemoglobin level < 12.0 g/dL
   • Creatinine clearance: <60 mL/min/1.73m2 as calculated by the equation of Modification of Diet in Renal Disease
   • QTc interval: > 450 ms
   • Positive serum tests (hepatitis B, hepatitis C, human immunodeficiency virus, syphilis)
5. Screening systolic blood pressure <90 mmHg or >150 mmHg and/or diastolic blood pressure <60 mmHg or >100 mmHg as measured in sitting position after ≥3 minutes of rest.
6. History of drug abuse or a positive urine screening test for drugs of abuse.
7. Prior or expected treatment with any prescription drugs or herbal medicine within 2 weeks and/or any over the counter drugs, health functional foods, or vitamins within 1 week prior to the planned first IP dosing (individuals who are determined to be eligible at the discretion of the investigator based on other criteria will be allowed to participate in the study).
8. Treatment with drug metabolizing enzyme inducers and/or suppressors such as barbitals within 1 month prior to the planned first IP dosing.
9. Having participated in another clinical trial or a bioequivalence study and administered any IP within 6 months prior to the planned first IP dosing in the present study.
10. Whole blood donation within 2 months and/or apheresis donation within 1 month and/or blood transfusion within 1 month prior to the planned first IP dosing.
11. Continuous, excessive caffeine intake or continuous alcohol intake or unable to refrain from caffeine/alcohol consumption during hospitalization.
12. Current smoker (individuals who stopped smoking 3 months prior may be included in the study) or unable to stop smoking from 3 months prior to the planned first IP dosing to the last hospital discharge.
13. Having had any foods containing grapefruits from 24 hours prior to hospital admission to discharge in each period/cohort and/or unable to refrain from having foods containing grapefruits during the same period of time.
14. Unable to refrain from having foods containing caffeine (coffee, tea [black tea, green tea, etc.], carbonated drink, coffee milk, nutrients and tonics, etc.) from 24 hours prior to hospital admission to discharge in each period/cohort.
15. Individual or his spouse/partner who is unable to use medically acceptable methods of contraception throughout the study plus for at least 3 months from the last IP dosing and who does not agree not to donate sperm during the same period of time.
16. Ineligible for study participation in the opinion of the investigator for other reasons including clinical laboratory test results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Cohort A(Food effect)	Drug: IDX-1197(After a meal); randomized, open-label, single-dose, 2-period, 2-sequence crossover study in healthy male Korean and Caucasian volunteers
Other: Cohort B(Single dose)	Drug: IDX-1197(fasting); open-label, single-dose study in Chinese male volunteers

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax of IDX-1197	PK parameters will be assessed using plasma IDX-1197 concentrations measured	through study completion, an average of 1 year
AUClast of IDX-1197	PK parameters will be assessed using plasma IDX-1197 concentrations measured	through study completion, an average of 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUCinf of IDX-1197	PK parameters will be assessed using plasma IDX-1197 concentrations measured	through study completion, an average of 1 year
Tmax of IDX-1197	PK parameters will be assessed using plasma IDX-1197 concentrations measured	through study completion, an average of 1 year
t1/2 of IDX-1197	PK parameters will be assessed using plasma IDX-1197 concentrations measured	through study completion, an average of 1 year
CL/F of IDX-1197	PK parameters will be assessed using plasma IDX-1197 concentrations measured	through study completion, an average of 1 year
Vd/F of IDX-1197	PK parameters will be assessed using plasma IDX-1197 concentrations measured	through study completion, an average of 1 year

Collaborators and Investigators

• Sponsor: Idience Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): January 16, 2022
• Primary Completion (Actual): July 23, 2022
• Study Completion (Actual): July 23, 2022

Study Registration Dates

• First Submitted: December 16, 2021
• First Submitted That Met QC Criteria: January 21, 2022
• First Posted (Actual): January 24, 2022

Study Record Updates

• Last Update Posted (Actual): August 9, 2022
• Last Update Submitted That Met QC Criteria: August 7, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Keywords: 1197; venadaparib; IDX-1197
• Other Study ID Numbers: ID-VDP-104

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No